Koon K Teo1, Marc Pfeffer2, Giuseppe Mancia3, Martin O'Donnell4, Gilles Dagenais5, Rafael Diaz6, Antonio Dans7, Lisheng Liu8, Jackie Bosch9, Philip Joseph9, Ingrid Copland9, Hyejung Jung9, Janice Pogue9, Salim Yusuf9. 1. Population Health Research Institute, McMaster-University-Hamilton Health Sciences, Hamilton, ON, Canada koon.teo@phri.ca teok@mcmaster.ca. 2. Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 3. Clinica Medica e Dipartimento di Medicina Clinica, Universita Milano-Bicocca, Ospedale San Gerardo di Monza, Milan, Italy. 4. Population Health Research Institute, McMaster-University-Hamilton Health Sciences, Hamilton, ON, Canada Health Research Board Clinical Research Facility, National University of Ireland Galway, Galway, Ireland. 5. Quebec Heart Institute, Hospital Laval, Ste-Foy, QC, Canada. 6. Estudios Clinicos Latinoamerica, Rosario, Argentina. 7. Section of Adult Medicine, College of Medicine, University of the Philippines, Manila, Philippines. 8. National Center for Cardiovascular Diseases, Cardiovascular Institute and FuWai Hospital, Chinese Academy of Medical Sciences, Beijing, China. 9. Population Health Research Institute, McMaster-University-Hamilton Health Sciences, Hamilton, ON, Canada.
Abstract
AIMS: We studied the unclear question whether blood pressure (BP) lowering reduces cardiovascular disease (CVD) in elderly individuals with systolic BP <160 mm Hg. METHODS AND RESULTS: We initiated a randomized placebo-controlled stratified 2 × 2 factorial clinical trial evaluating the effects of BP lowering in 11 000 elderly individuals with systolic blood pressure (SBP) between 130 and 159 mm Hg, for 5 years. Following 5-week active run-in, participants were randomized to aliskiren (300 mg) or placebo, and to an additional antihypertensive [hydrochlorothiazide (25 mg) or amlodipine (5 mg)], or their respective placeboes. Study was terminated by sponsor after 1759 subjects (age 72.1± 5.2 years, 88% receiving at least one antihypertensive) were randomized and followed for 0.6 year. Study drugs were well tolerated with few serious adverse events during run-in and after randomization, with no significant differences between treatment groups. By design, three levels of BP reductions were achieved, adjusted mean BP reductions of 3.5/1.7 mm Hg (P < 0.001) by aliskiren, 6.8/3.3 mm Hg (P < 0.001) by hydrochlorothiazide or amlodipine, and 10.3/5.0 mm Hg (P < 0.001) by double therapy compared with placebo. Twenty-five major CVD events occurred. Non-significant trends towards fewer CVD events with greater BP reductions are evident: hazard ratios (HR) 0.82 [95% confidence interval (CI): 0.37-1.81] for 3.5 mm Hg SBP reduction; HR 0.45 (95% CI: 0.19-1.04) for 6.8 mm Hg; and HR 0.25 (0.05-1.18) for 10.3 mm Hg reduction for primary composite of CV death, MI, stroke, or significant heart failure. CONCLUSIONS: Sizeable reductions in BP, with potential for substantial CVD reduction, can be safely achieved using combinations of BP drugs in the elderly with normal high and Stage 1 hypertension. CLINICAL TRIAL REGISTRATION: NCT01259297. Published on behalf of the European Society of Cardiology. All rights reserved.
RCT Entities:
AIMS: We studied the unclear question whether blood pressure (BP) lowering reduces cardiovascular disease (CVD) in elderly individuals with systolic BP <160 mm Hg. METHODS AND RESULTS: We initiated a randomized placebo-controlled stratified 2 × 2 factorial clinical trial evaluating the effects of BP lowering in 11 000 elderly individuals with systolic blood pressure (SBP) between 130 and 159 mm Hg, for 5 years. Following 5-week active run-in, participants were randomized to aliskiren (300 mg) or placebo, and to an additional antihypertensive [hydrochlorothiazide (25 mg) or amlodipine (5 mg)], or their respective placeboes. Study was terminated by sponsor after 1759 subjects (age 72.1 ± 5.2 years, 88% receiving at least one antihypertensive) were randomized and followed for 0.6 year. Study drugs were well tolerated with few serious adverse events during run-in and after randomization, with no significant differences between treatment groups. By design, three levels of BP reductions were achieved, adjusted mean BP reductions of 3.5/1.7 mm Hg (P < 0.001) by aliskiren, 6.8/3.3 mm Hg (P < 0.001) by hydrochlorothiazide or amlodipine, and 10.3/5.0 mm Hg (P < 0.001) by double therapy compared with placebo. Twenty-five major CVD events occurred. Non-significant trends towards fewer CVD events with greater BP reductions are evident: hazard ratios (HR) 0.82 [95% confidence interval (CI): 0.37-1.81] for 3.5 mm Hg SBP reduction; HR 0.45 (95% CI: 0.19-1.04) for 6.8 mm Hg; and HR 0.25 (0.05-1.18) for 10.3 mm Hg reduction for primary composite of CV death, MI, stroke, or significant heart failure. CONCLUSIONS: Sizeable reductions in BP, with potential for substantial CVD reduction, can be safely achieved using combinations of BP drugs in the elderly with normal high and Stage 1 hypertension. CLINICAL TRIAL REGISTRATION: NCT01259297. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Giuseppe Mancia; Guy De Backer; Anna Dominiczak; Renata Cifkova; Robert Fagard; Giuseppe Germano; Guido Grassi; Anthony M Heagerty; Sverre E Kjeldsen; Stephane Laurent; Krzysztof Narkiewicz; Luis Ruilope; Andrzej Rynkiewicz; Roland E Schmieder; Harry A J Struijker Boudier; Alberto Zanchetti; Alec Vahanian; John Camm; Raffaele De Caterina; Veronica Dean; Kenneth Dickstein; Gerasimos Filippatos; Christian Funck-Brentano; Irene Hellemans; Steen Dalby Kristensen; Keith McGregor; Udo Sechtem; Sigmund Silber; Michal Tendera; Petr Widimsky; José Luis Zamorano; Serap Erdine; Wolfgang Kiowski; Enrico Agabiti-Rosei; Ettore Ambrosioni; Lars H Lindholm; Margus Viigimaa; Stamatis Adamopoulos; Enrico Agabiti-Rosei; Ettore Ambrosioni; Vicente Bertomeu; Denis Clement; Serap Erdine; Csaba Farsang; Dan Gaita; Gregory Lip; Jean-Michel Mallion; Athanasios J Manolis; Peter M Nilsson; Eoin O'Brien; Piotr Ponikowski; Josep Redon; Frank Ruschitzka; Juan Tamargo; Pieter van Zwieten; Bernard Waeber; Bryan Williams Journal: J Hypertens Date: 2007-06 Impact factor: 4.844
Authors: Alan H Gradman; Roland E Schmieder; Robert L Lins; Juerg Nussberger; Yanntong Chiang; Martin P Bedigian Journal: Circulation Date: 2005-02-21 Impact factor: 29.690
Authors: James L Pool; Roland E Schmieder; Michel Azizi; Jean-Claude Aldigier; Andrzej Januszewicz; Walter Zidek; Yanntong Chiang; Andrew Satlin Journal: Am J Hypertens Date: 2007-01 Impact factor: 2.689
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190
Authors: Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg Journal: N Engl J Med Date: 2008-06-05 Impact factor: 91.245
Authors: Hans-Henrik Parving; Barry M Brenner; John J V McMurray; Dick de Zeeuw; Steven M Haffner; Scott D Solomon; Nish Chaturvedi; Frederik Persson; Akshay S Desai; Maria Nicolaides; Alexia Richard; Zhihua Xiang; Patrick Brunel; Marc A Pfeffer Journal: N Engl J Med Date: 2012-11-03 Impact factor: 91.245
Authors: Michael Walsh; Braden Manns; Amit X Garg; Joe Bueti; Christian Rabbat; Andrew Smyth; Jessica Tyrwhitt; Jackie Bosch; Peggy Gao; P J Devereaux; Ron Wald Journal: Clin J Am Soc Nephrol Date: 2015-07-02 Impact factor: 8.237